Search results
Showing 286 to 300 of 698 results for must
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)
Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
botulinum toxin need not be modified for inclusion, but entrants into a trial must have anatomically normal kidneys (on imaging) and...
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
development of such recommendations and guidelines and other information. 4. Users must only use the site for purposes consistent with...
. Patient selection should be done by a multidisciplinary team, which must include interventional cardiologists experienced in the...
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
NICE has developed a medtech innovation briefing (MIB) on End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia .
Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)
NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest
This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Show all sections